MF

Meredith Fisher

Co-founding CEO and Director at Violet Therapeutics

Cambridge, Massachusetts

Overview 

Meredith Fisher is a Partner at Mass General Brigham Ventures, with a background as a Co-founding CEO and Director at Violet Therapeutics and Mediar Therapeutics. She holds a PhD from Harvard University and an MBA from Massachusetts Institute of Technology. Fisher's career highlights include co-founding and leading successful biotech companies, along with her current role as a Partner at a prominent venture capital firm focusing on investments in the BioTech sector, primarily in the Boston/New England area.

Work Experience 

  • Co-founding CEO and Director

    2022 - Current

Violet Therapeutics is a pre-clinical stage company leveraging first-in-class platforms to identify, map, and mine the cellular connectome.

Raised $10,600,000.00 from Mass General Brigham Ventures, Ono Venture Investment, UTEC - The University of Tokyo Edge Capital Partners and Dementia Discovery Fund.

  • Partner, Mass General Brigham Ventures

    2016

    Mass General Brigham Ventures is an early-stage venture capital firm founded in 2008 to advance new science and technology based on discovery and invention originating from Mass General Brigham. The fund invests in medical innovations created by MGB’s world-class research hospitals. We invest in leading-edge life science technologies with the goal of bringing discoveries, inventions and innovations from MGB to market for the benefit of patients worldwide. Portfolio: FireCyte, Violet, Nocion, Mediar, Amolyt Pharma, ZielBio, Scorpion and Claris Bio

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham that invests in early-stage companies.

  • Co-founding CEO and Director

    2019 - 2023

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

Raised $105,000,000.00 from Pureos Bioventures, Novartis Venture Fund, Mass General Brigham Ventures, Ono Venture Investment, Mission BioCapital, Pfizer Venture Investments, Gimv, Sofinnova Partners, Eli Lilly & Company Foundation and Bristol-Myers Squibb.

  • Director, Private Investments

    2013 - 2015

Bracebridge manages assets for a diverse, sophisticated, global investor base that includes endowments, foundations, pensions, and high net.

  • Head, Business Development

    2012 - 2013

    Ginkgo Bioworks designs custom microbes for customers across multiple markets, developing new organisms that replace technology with biology. www.ginkgobioworks.com

Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.

Raised $1,575,403,063.00 from Bill & Melinda Gates Foundation, Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention and Agriculture and Food Research Initiative.

  • Senior Director of Technology & Business Development at Enlight Biosciences

    2009 - 2012

    Enlight is a venture creation firm founded by PureTech Ventures.

  • Associate Scientist

    2001 - 2002

  • Associate Scientist

    1998 - 2000

Articles About Meredith

Relevant Websites